Compass Therapeutics Presents Biomarker Data Related To CTX-471 Clinical Activity At SITC Annual Meeting
Compass Therapeutics Presents Biomarker Data Related To CTX-471 Clinical Activity At SITC Annual Meeting
compass therapeutics在海豐國際年會上介紹了與CTX-471臨床活動相關的生物標誌數據
- New data showed a correlation between the levels of neural cell adhesion molecule (NCAM or CD56) expression and response and disease control in patients treated with CTX-471 monotherapy.
- Predictive biomarkers correlated with response and changes in pharmacodynamic markers were seen in patients treated with CTX-471, a novel anti-CD137 agonist antibody, in an analysis from the Phase 1 monotherapy study.
- 新數據顯示，在接受CTX-471單藥治療的患者中，神經細胞粘附分子（NCAm或CD56）的表達水平與治療反應和疾病控制之間存在相關性。
- 在接受CTX-471治療的患者中，預測性生物標誌物與治療反應和藥效動力學標誌物的變化相關，並在1期單藥研究的分析中觀察到這些現象。CTX-471是一種新型抗CD137激動劑抗體。
資訊熱榜
更新時間